QIAGEN is a global leader in providing molecular testing solutions that enable researchers and clinicians to unlock valuable insights from DNA, RNA, and proteins. Operating in the life sciences and diagnostics markets, QIAGEN serves a diverse range of clients including academic institutions, pharmaceutical companies, and clinical laboratories. The company offers a comprehensive portfolio of products, including sample technologies, assay technologies, and bioinformatics software, designed to streamline the workflow from sample collection to data interpretation.

QIAGEN's business model revolves around the sale of consumables, instruments, and software solutions. The company generates revenue through the direct sale of these products, as well as through service contracts and licensing agreements. By focusing on innovation and customer-centric solutions, QIAGEN aims to address the evolving needs of the molecular biology and diagnostics sectors.

Key products include the QIAseq UPXome RNA Library Kits, which maximize gene expression insights from minimal RNA amounts, and the QIAstat Dx Viral Vesicular Panel, which enhances research and surveillance efforts for viruses like monkeypox. Additionally, QIAGEN offers the QIAstat Dx Analyzer, a fully integrated and scalable digital PCR system that delivers precise results quickly and efficiently.

Keywords: molecular testing, DNA analysis, RNA analysis, protein analysis, life sciences, diagnostics, sample technologies, assay technologies, bioinformatics, QIAstat Dx.